PDF(Pubmed)
Abstract：
BACKGROUND: Prostate cancer is the second most common cancer in males worldwide, and its incidence is rising. Early detection is crucial for improving the outcomes, but the current screening methods have limitations. While prostate-specific antigen (PSA) testing is the most widely used screening tool, it has poor specificity, leading to a high rate of false positives and unnecessary biopsies. The existing biopsy techniques are invasive and are associated with complications. The liquid biopsy methods that analyze the biomarkers in blood or other bodily fluids offer a non-invasive and more accurate alternative for detecting and characterizing prostate tumors.
METHODS: Here, we present a novel liquid biopsy method for prostate cancer based on the identification of specific proteins in the extracellular vesicles isolated from the blood of patients with prostate cancer.
RESULTS: We observed that a specific combination of sEV proteins is a sensitive indicator of prostate cancer. Indeed, we found that the number of clusters expressed by specific combinations of either intra-vesicular (STAT3 and CyclinD1) or surface proteins (ERBB3, ALK, and CD81) allowed us to significantly discriminate the patients with prostate cancer from the individuals with hyperplasia.
CONCLUSIONS: This new liquid biopsy method has the potential to improve prostate cancer screening by providing a non-invasive and more accurate diagnostic tool.
METHODS: Here, we present a novel liquid biopsy method for prostate cancer based on the identification of specific proteins in the extracellular vesicles isolated from the blood of patients with prostate cancer.
RESULTS: We observed that a specific combination of sEV proteins is a sensitive indicator of prostate cancer. Indeed, we found that the number of clusters expressed by specific combinations of either intra-vesicular (STAT3 and CyclinD1) or surface proteins (ERBB3, ALK, and CD81) allowed us to significantly discriminate the patients with prostate cancer from the individuals with hyperplasia.
CONCLUSIONS: This new liquid biopsy method has the potential to improve prostate cancer screening by providing a non-invasive and more accurate diagnostic tool.
摘要：
背景：前列腺癌是全球男性中第二常见的癌症，其发病率正在上升。早期发现对于改善结果至关重要，但目前的筛查方法有局限性。虽然前列腺特异性抗原（PSA）检测是最广泛使用的筛查工具，它的特异性差，导致高的假阳性率和不必要的活检。现有的活检技术是侵入性的并且与并发症相关。分析血液或其他体液中的生物标志物的液体活检方法为检测和表征前列腺肿瘤提供了非侵入性且更准确的替代方案。
方法：这里，我们提出了一种新的前列腺癌液体活检方法，该方法基于从前列腺癌患者血液中分离的细胞外囊泡中的特定蛋白质的鉴定。
结果：我们观察到sEV蛋白的特定组合是前列腺癌的敏感指标。的确,我们发现，通过囊泡内（STAT3和CyclinD1）或表面蛋白（ERBB3，ALK，和CD81）使我们能够显着区分前列腺癌患者和增生患者。
结论：这种新的液体活检方法具有通过提供非侵入性且更准确的诊断工具来改善前列腺癌筛查的潜力。
方法：这里，我们提出了一种新的前列腺癌液体活检方法，该方法基于从前列腺癌患者血液中分离的细胞外囊泡中的特定蛋白质的鉴定。
结果：我们观察到sEV蛋白的特定组合是前列腺癌的敏感指标。的确,我们发现，通过囊泡内（STAT3和CyclinD1）或表面蛋白（ERBB3，ALK，和CD81）使我们能够显着区分前列腺癌患者和增生患者。
结论：这种新的液体活检方法具有通过提供非侵入性且更准确的诊断工具来改善前列腺癌筛查的潜力。
